Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 3771

1.

Medical Treatments for Acromegaly: A Systematic Review and Network Meta-Analysis.

Leonart LP, Ferreira VL, Tonin FS, Fernandez-Llimos F, Pontarolo R.

Value Health. 2018 Jul;21(7):874-880. doi: 10.1016/j.jval.2017.12.014. Epub 2018 Feb 8. Review.

PMID:
30005760
2.

COMPARISON OF CABERGOLINE VERSUS RALOXIFENE ADD-ON THERAPY TO LONG-ACTING SOMATOSTATIN ANALOGUE IN PATIENTS WITH INADEQUATELY CONTROLLED ACROMEGALY: A RANDOMIZED OPEN LABEL CLINICAL TRIAL.

Imani M, Khamseh ME, Asadi P, Ghorbani M, Akbari H, Alaei-Shahmiri F, Honardoost M, Kaynama MR, Malek M.

Endocr Pract. 2018 Jun;24(6):542-547. doi: 10.4158/EP-2017-0195.

PMID:
29949429
3.

Mortality in acromegaly decreased in the last decade: a systematic review and meta-analysis.

Bolfi F, Neves AF, Boguszewski CL, Nunes-Nogueira VS.

Eur J Endocrinol. 2018 Jul;179(1):59-71. doi: 10.1530/EJE-18-0255. Epub 2018 May 15. Review.

PMID:
29764907
4.

USE OF ELECTRONIC HEALTH RECORDS TO CHARACTERIZE A RARE DISEASE IN THE U.S.: TREATMENT, COMORBIDITIES, AND FOLLOW-UP TRENDS AMONG PATIENTS WITH A CONFIRMED DIAGNOSIS OF ACROMEGALY.

Silverstein JM, Roe ED, Munir KM, Fox JL, Emir B, Kouznetsova M, Lamerato LE, King D.

Endocr Pract. 2018 Jun;24(6):517-526. doi: 10.4158/EP-2017-0243. Epub 2018 Apr 6.

PMID:
29624099
5.

Acromegalic cardiomyopathy: Epidemiology, diagnosis, and management.

Sharma AN, Tan M, Amsterdam EA, Singh GD.

Clin Cardiol. 2018 Mar;41(3):419-425. doi: 10.1002/clc.22867. Epub 2018 Mar 25. Review.

6.

Decreasing mortality and changes in treatment patterns in patients with acromegaly from a nationwide study.

Esposito D, Ragnarsson O, Granfeldt D, Marlow T, Johannsson G, Olsson DS.

Eur J Endocrinol. 2018 May;178(5):459-469. doi: 10.1530/EJE-18-0015. Epub 2018 Feb 26.

PMID:
29483205
7.

Dermatologic manifestations of acromegaly: A case in point and a focused review.

Degirmentepe EN, Gungor S, Kocaturk E, Kiziltac U, Adas M, Ozekinci S, Khachemoune A.

Dermatol Online J. 2017 Aug 15;23(8). pii: 13030/qt50s903qh.

PMID:
29469738
8.

The comprehensive impact on human body induced by resolution of growth hormone excess.

Zhang Z, Li Q, He W, Qiu H, Ye H, Wang Y, Shen M, He M, Yu Y, Shou X, Huang C, Yu H, Huang G, Tang W, Geng D, Fu C, Liu C, Ma Z, Ye Z, Zhang Q, Zhang Y, Shen Y, Yang Y, Wang M, Liu X, Lu Y, Hu R, Mao Y, Zhou L, Li Y, Li S, Tritos NA, Zhao Y.

Eur J Endocrinol. 2018 Apr;178(4):365-375. doi: 10.1530/EJE-17-0872. Epub 2018 Jan 31.

PMID:
29386229
9.

Effects of active acromegaly on bone mRNA and microRNA expression patterns.

Belaya Z, Grebennikova T, Melnichenko G, Nikitin A, Solodovnikov A, Brovkina O, Grigoriev A, Rozhinskaya L, Lutsenko A, Dedov I.

Eur J Endocrinol. 2018 Apr;178(4):353-364. doi: 10.1530/EJE-17-0772. Epub 2018 Jan 26.

PMID:
29374071
10.

Increasing frequency of combination medical therapy in the treatment of acromegaly with the GH receptor antagonist pegvisomant.

Strasburger CJ, Mattsson A, Wilton P, Aydin F, Hey-Hadavi J, Biller BMK.

Eur J Endocrinol. 2018 Apr;178(4):321-329. doi: 10.1530/EJE-17-0996. Epub 2018 Jan 25.

11.

Efficacy of combined treatment with pasireotide, pegvisomant and cabergoline in an acromegalic patient resistant to other treatments: a case report.

Ciresi A, Radellini S, Guarnotta V, Giordano C.

BMC Endocr Disord. 2018 Jan 24;18(1):2. doi: 10.1186/s12902-018-0231-9.

12.

MANAGEMENT OF ENDOCRINE DISEASE: Personalized medicine in the treatment of acromegaly.

Kasuki L, Wildemberg LE, Gadelha MR.

Eur J Endocrinol. 2018 Mar;178(3):R89-R100. doi: 10.1530/EJE-17-1006. Epub 2018 Jan 16. Review.

PMID:
29339530
13.

Variable skeletal anatomical features of acromegaly in the skull and craniocervical junction.

Piagkou M, Manolakos O, Troupis T, Lazaridis N, Laios K, Samolis A, Natsis K.

Acta Med Acad. 2017 Nov;46(2):162-168. doi: 10.5644/ama2006-124.201.

14.

Pregnancy in a woman with acromegaly after transsphenoidal partial resection of pituitary macroadenoma - a case report.

Tomczyk K, Rzymski P, Woźniak J, Wilczak M.

Pol Merkur Lekarski. 2017 Dec 22;43(258):268-271.

PMID:
29298966
15.

Age- and Sex-Specific Differences as Predictors of Surgical Remission Among Patients With Acromegaly.

Park SH, Ku CR, Moon JH, Kim EH, Kim SH, Lee EJ.

J Clin Endocrinol Metab. 2018 Mar 1;103(3):909-916. doi: 10.1210/jc.2017-01844.

PMID:
29272449
16.

Automatic Detection of Acromegaly From Facial Photographs Using Machine Learning Methods.

Kong X, Gong S, Su L, Howard N, Kong Y.

EBioMedicine. 2018 Jan;27:94-102. doi: 10.1016/j.ebiom.2017.12.015. Epub 2017 Dec 15.

17.

Expression of E-cadherin, Slug and NCAM and its relationship to tumor invasiveness in patients with acromegaly.

Mendes GA, Haag T, Trott G, Rech CGSL, Ferreira NP, Oliveira MC, Kohek MB, Pereira-Lima JFS.

Braz J Med Biol Res. 2017 Dec 11;51(2):e6808. doi: 10.1590/1414-431X20176808.

18.

Pregnancy in women after successful acromegaly treatment, including surgical removal of pituitary adenoma and postoperative therapy using lanreotide acetate.

Teltayev D, Akshulakov S, Ryskeldiev N, Mustafin K, Vyacheslav L.

Gynecol Endocrinol. 2017;33(sup1):50-51. doi: 10.1080/09513590.2017.1404240.

PMID:
29264984
19.

Mapping AcroQoL scores to EQ-5D to obtain utility values for patients with acromegaly.

Badia X, Trainer P, Biermasz NR, Tiemensma J, Carreño A, Roset M, Forsythe A, Webb SM.

J Med Econ. 2018 Apr;21(4):382-389. doi: 10.1080/13696998.2017.1419960. Epub 2018 Jan 5.

PMID:
29261359
20.

Insulin-mediated pseudoacromegaly: a report of two pediatric patients.

Inman M, Nour MA.

J Pediatr Endocrinol Metab. 2018 Jan 26;31(2):235-238. doi: 10.1515/jpem-2017-0398.

PMID:
29252200

Supplemental Content

Loading ...
Support Center